ChemoCentryx (NASDAQ:CCXI) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership and risk.
Volatility and Risk
ChemoCentryx has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.16, suggesting that its share price is 84% less volatile than the S&P 500.
Valuation & Earnings
This table compares ChemoCentryx and Regeneron Pharmaceuticals' top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
|---|
| ChemoCentryx | $64.89 million | 17.85 | $-55,360,000.00 | ($0.84) | -19.73 |
| Regeneron Pharmaceuticals | $8.50 billion | 8.21 | $3.51 billion | $28.66 | 22.75 |
Regeneron Pharmaceuticals has higher revenue and earnings than ChemoCentryx. ChemoCentryx is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares ChemoCentryx and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
|---|
| ChemoCentryx | -568.54% | -33.17% | -24.34% |
| Regeneron Pharmaceuticals | 50.11% | 50.43% | 33.56% |
Analyst Recommendations
This is a breakdown of recent ratings and price targets for ChemoCentryx and Regeneron Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
|---|
| ChemoCentryx | 1 | 2 | 5 | 0 | 2.50 |
| Regeneron Pharmaceuticals | 0 | 4 | 13 | 0 | 2.76 |
ChemoCentryx presently has a consensus price target of $37.8750, suggesting a potential upside of 128.58%. Regeneron Pharmaceuticals has a consensus price target of $698.3750, suggesting a potential upside of 7.13%. Given ChemoCentryx's higher probable upside, research analysts plainly believe ChemoCentryx is more favorable than Regeneron Pharmaceuticals.
Institutional and Insider Ownership
63.2% of ChemoCentryx shares are owned by institutional investors. Comparatively, 82.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 8.0% of ChemoCentryx shares are owned by company insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Regeneron Pharmaceuticals beats ChemoCentryx on 11 of the 14 factors compared between the two stocks.
